loading page

Amrubicin for relapsed Extensive-Disease small-cell lung cancer: a systematic review and meta-analysis
  • +1
  • ziling Liu,
  • Xiaofeng Cong,
  • Pengfei Cui,
  • Lei Yang
ziling Liu
Department of oncology, first hospital of Jilin university, changchun, China
Author Profile
Xiaofeng Cong
Department of oncology, first hospital of Jilin university, changchun, China
Author Profile
Pengfei Cui
Department of oncology, first hospital of Jilin university, changchun, China
Author Profile
Lei Yang
Department of oncology, first hospital of Jilin university, changchun, China
Author Profile

Abstract

Background: Amrubicin (AMR), a third-generation anthracycline and potent topoisomerase II inhibitor, has been known to be effective treatment for previously treated Extensive-Disease Small-Cell Lung Cancer (ED-SCLC). However, the efficacy and toxicityof amrubicin remainsconflicting . Thus,this meta-analysis was designed to evaluate amrubicin effectiveness in refractory ED-SCLC patients. Methods: Pubmed, Embase, Cochrane library databases were searched for the relevant articles. After rigorous evaluation on quality, the data extraction process was carried from eligible randomized controlled trials (RCTs). Meta-analysis Revman 5.3 software was used for statistical analysis. Results: A total of 7 RCTs were included in our analysis. The regimen of AMR was associate with better progression-free survival (PFS)(OR=0.81,95%CI=0.71-0.92, P=0.001), and the objective response rate (ORR) (OR=1.83,95%CI=1.37-2.45, P<0.0001=. While, there was no statistical significance was found in terms of the overall survival (OS) (OR=0.90,95%CI=0.79-1.03, P=0.12). The frequencies of the most common toxicities were more commonly occurred in the AMR group compared with the control group were neutropenia (OR=1.67, 95%CI=1.10-2.54, P= 0.02) and anemia (OR=0.47,95%CI=0.34-0.66, P<0.0001= , respectively. Conclusion: AMR was associated with better efficacy and acceptable side effects for the treatment-refractory ED-SCLC. The findings revealed that amrubicin may be used as second-line chemotherapy for patients with sensitive-relapse ED-SCLC.